ONGLYZA 2.5mg Price

Overview

Welcome to Dwaey, specifically on ONGLYZA 2.5mg page.
This medicine contains an important and useful components, as it consists of
Saxagliptinis available in the market in concentration

Name

Saxagliptin

Precaution

Renal impairment Decrease dose with strong CYP450 3A4/5 inhibitors Coadministration with thiazolidinediones (eg, rosiglitazone, pioglitazone) increases risk for peripheral edema Pancreatitis reported with saxagliptin; monitor for signs and symptoms and discontinue if pancreatitis suspected Serious hypersensitivity reactions with saxagliptin reported (typically within the first 3 months of therapy) History of angioedema Coadministration with a sulfonylurea or with insulin may increase hypoglycemia; monitor closely and adjust sulfonylurea and/or insulin dose accordingly Congestive heart failure (CHF) risks. Observe patients for signs and symptoms of heart failure during therapy; Lactation: Not known whether distributed in breast milk; caution advised

Indication

Type 2 diabetes

Contra indication

Documented hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions)

Side Effect

1-10% (selected) Urinary tract infection (7%),Headache (7%),Hypersensitivity-related events (<4%; eg, urticaria, facial edema),Peripheral edema (<4%; increased incidence when coadministered with thiazolidinediones),Upper respiratory tract infection (3%),Gastroenteritis (2%),Hypoglycemia (1.6%) Frequency Not Defined Increased creatinine phosphokinase,Increased creatinine,Idiopathic thrombocytopenic purpura rash

Pregnancy Category ID

2

Mode of Action

Dipeptidyl peptidase IV (DPP-4) inhibition that results in increased incretin hormones and enhanced glycemic control.

Interaction

Strong CYP3A4/5 inhibitors (eg ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir & telithromycin).

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration